Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial
抗TIM-3抗体TQB2618联合penpulimab治疗既往接受过PD-1/PD-L1靶向治疗的复发或难治性经典霍奇金淋巴瘤:一项多中心、开放标签、单臂Ib期临床试验
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2026-014968
Hong, Huangming; Chen, Zegeng; Cui, Jie; Zhang, Qingyuan; Li, Ping; Tao, Rong; Huang, He; Wang, Binghua; Li, Wuping; Wu, Hui; Wei, Jin; Su, Liping; Zhang, Zhihua; Zhong, Mingxing; Wang, Huaqing; Wang, Cong; Zhou, Hui; Wang, Jishi; Dong, Min; Lin, Tongyu